Not yet recruitingInterventionalNot ApplicableLast updated Aug 11, 2026

Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis

Effectiveness and Safety of Tezepelumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience

Overview

ClinicalTrials.gov ID: NCT07757841
Lead Sponsor: Qianfoshan HospitalOTHER
Brief Summary: An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
Study Type: Interventional

Status

Study Record Dates

NCT07530770Recruiting

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

NCT05280418Completed

Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma

NCT05329194Completed

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT04108962Withdrawn

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

NCT03927157Completed

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

NCT05129033Unknown status

A Prospective Study on Optimizing Treatment for ABPA